Arvinas (NASDAQ: ARVN) — Company Overview, News & Financial Data
Arvinas develops protein degradation therapeutics aimed at treating cancer and other diseases using their PROTAC® technology.
Arvinas
Arvinas (NASDAQ:ARVN) focuses on developing protein degradation therapeutics aimed at fighting cancer and other diseases. This innovative approach seeks to use the body's own machinery to degrade and remove disease-causing proteins. Their projects revolve around leveraging their proprietary PROTAC® Discovery Engine to advance a pipeline of novel drug candidates that have the potential to bring new treatments to patients in need. Arvinas' objectives center on progressing these drug candidates through clinical trials, with a strong emphasis on those targeting prostate and breast cancer. By harnessing the power of protein degradation, Arvinas aims to create a new class of drugs that could provide significant benefits over traditional therapies.
Snapshot
Operations
Products and/or services of Arvinas
- PROTAC Protein Degraders - A novel class of drugs that target disease-causing proteins for degradation.
- ARV-110 for Prostate Cancer - An investigational PROTAC protein degrader targeting androgen receptor (AR) driven diseases.
- ARV-471 for Breast Cancer - A pioneering PROTAC protein degrader specifically aiming at estrogen receptor (ER) positive diseases.
- Drug Discovery Platform - A versatile platform for developing a broad range of PROTAC-based therapies targeting various diseases.
- Partnerships in Pharma - Collaborations with larger pharmaceutical companies to expand the application and development of PROTAC technology.
- Clinical Development Program - A comprehensive program dedicated to advancing the clinical trials of PROTAC-based therapies for various cancers.
Arvinas executive team
- Andrew R. SaikCFO & Treasurer
- Angela M. CacaceChief Scientific Officer
- Randy TeelCEO, President & Director
- David K. LoomisVP & Chief Accounting Officer
- Jeff BoyleVice President of Investor Relations
- Jared M. FreedbergGeneral Counsel & Corporate Secretary
- Steve WeissSenior VP & Chief Human Resources Officer
- Kelly PageSenior VP & Global Head of Oncology Strategy and Program Leadership
Key financials
Reported results for Arvinas, in USD.
- Market cap
- 491.7M
- Revenue (TTM)
- 316.7M
- P/E ratio
- 30.1
- EPS (diluted, TTM)
- 0.3
- Dividend yield
- —
- Profit margin
- 2.9%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 262.6M | -114.9M | -80.8M | |
| 263.4M | -250.2M | -198.9M | |
| 78.5M | -401.5M | -367.3M | |
| 131.4M | -263.2M | -271.9M |